Table 2.
The clinical characteristics of patients with different BRAFV600E mutations
| Characteristics | Mutation type (n) | Wild type (n) | P‐value | ||
|---|---|---|---|---|---|
| Children | Gender | Male | 3 | 11 | 1.00 |
| Female | 2 | 6 | |||
| LCH subtype | SS | 2 | 6 | 1.00 | |
| MS‐RO+ & MS‐RO− | 3 | 9 | |||
| Lung involvement | Yes | 1 | 6 | 1.00 | |
| No | 4 | 11 | |||
| Pituitary involvement | Yes | 3 | 15 | 0.21 | |
| No | 2 | 2 | |||
| Thyroid involvement | Yes | 0 | 2 | 1.00 | |
| No | 5 | 15 | |||
| Prognosis | Cured/improved/stable | 5 | 16 | 1.00 | |
| Exacerbation/relapse/died | 0 | 1 | |||
| Adults | Gender | Male | 6 | 26 | 0.63 |
| Female | 4 | 9 | |||
| LCH subtype | SS | 1 | 9 | 0.53 | |
| MS‐RO+ & MS‐RO− | 9 | 26 | |||
| Lung involvement | Yes | 5 | 21 | 0.84 | |
| No | 5 | 14 | |||
| Pituitary involvement | Yes | 5 | 19 | 1.00 | |
| No | 5 | 16 | |||
| Thyroid involvement | Yes | 1 | 5 | 1.00 | |
| No | 9 | 30 | |||
| Prognosis | Cured/improved/stable | 9 | 30 | 1.00 | |
| Exacerbation/relapse/died | 1 | 5 | |||
LCH, Langerhans cell histiocytosis; MS, multisystem; RO, risk organ; SS, single system.